Pen Injectors Market Forecasts to 2030 – Global Analysis By Type (Disposable and Reusable), Dosage (Fixed Dosage, Variable Dosage, Half-Unit Dosage, Specialized Dosage and Other Dosages), Therapy, Distribution Channel, End User and By Geography

Pen Injectors Market Forecasts to 2030 – Global Analysis By Type (Disposable and Reusable), Dosage (Fixed Dosage, Variable Dosage, Half-Unit Dosage, Specialized Dosage and Other Dosages), Therapy, Distribution Channel, End User and By Geography

According to Stratistics MRC, the Global Pen Injectors Market is accounted for $48.82 billion in 2023 and is expected to reach $75.81 billion by 2030 growing at a CAGR of 9.2% during the forecast period. Pen injectors are medical devices designed to administer precise doses of medication to patients. They are often used for self-injection of various types of medication, including insulin, growth hormones, certain biologic drugs, and other injectables. Pen injectors are widely used by patients with chronic conditions such as diabetes, multiple sclerosis, rheumatoid arthritis, and more. They are designed to be user-friendly, making them easy for patients to handle and administer their medication, even without professional medical assistance.

According to Caspersen et al, in 2020, about 10.9 million people aged above 65 years were estimated to have been diagnosed with diabetes in the U.S, and this number is projected to reach 26.7 million by 2050.

Market Dynamics:

Driver:

Increasing advancements in biologic therapies

Biologic therapies often require precise dosages due to their complex molecular structures and mechanisms of action. Pen injectors are designed to deliver accurate and consistent dosages, making them well-suited for biologic medications. Also, Pen injectors enable patients to self-administer their biologic therapies, reducing the need for frequent visits to healthcare facilities. Additionally, the convenience and ease of use associated with pen injectors can lead to improved patient compliance and adherence to prescribed biologic therapies which fuels the market demand.

Restraint:

Limited compatibility with certain medications

Healthcare providers may be hesitant to prescribe or recommend pen injectors if they are not compatible with a wide range of medications. Patients who require multiple medications, some of which are not compatible with the pen injector, may find it inconvenient or burdensome to use different administration methods. This can lead to decreased patient satisfaction and compliance. Manufacturers may miss out on business opportunities with pharmaceutical companies. This could result in lost partnerships and contracts.

Opportunity:

Integration with digital health solutions

Pen injector’s integration with digital health solutions offers a range of benefits and applications for both patients and healthcare providers. It allows patients to track and monitor their medication doses. Digital health platforms can send reminders and alerts to patients, prompting them to take their medication at the prescribed times. Based on the data collected, healthcare providers can make informed decisions about medication titration or adjustments to optimize treatment outcomes. Further, it also enhances patient engagement, reduces hospitalizations, and provides insights for specific conditions which boost the market growth.

Threat:

Competition from alternative drug delivery methods

Alternative drug delivery methods, such as oral tablets, inhalers, patches, and even newer technologies like smart pills or implantable devices, offer patients a range of options. Some patients may prefer alternative methods of drug delivery over pen injectors with a fear of needles. Further, certain conditions may respond better to inhalable or oral forms of medication compared to injectables. Additionally, innovation and improvements in alternative methods, making them more attractive to patients and healthcare providers which impedes the market growth.

Covid-19 Impact

The pen injectors market, which is a part of the medical device industry, likely experienced both positive and negative effects during the pandemic. The rise of telemedicine and remote monitoring during the pandemic may have influenced the adoption of pen injectors, as they are conducive to self-administration and remote monitoring of chronic conditions. Economic uncertainty and shifts in healthcare priorities may have led to market consolidation. The epidemic has affected the vaccination rates, and the emergence of new variants.

The diabetes segment is expected to be the largest during the forecast period

The diabetes segment is estimated to have a lucrative growth. Pen injectors allow for precise and accurate dosing of insulin, ensuring that individuals receive the correct amount of medication. Pen injectors are compact, lightweight, and easy to carry, making them convenient for individuals who need to administer insulin on the go. They use fine-gauge needles, which can result in less pain and discomfort during injection. Its user-friendly nature, customizable dosing and discreet administration propels the segment demand.

The home-care settings segment is expected to have the highest CAGR during the forecast period

The home-care settings segment is anticipated to witness the highest CAGR growth during the forecast period, due to its convenience and effectiveness. Pen injectors are designed to be user-friendly, often featuring simple mechanisms for loading and administering medication. They are compact and portable, allowing patients to administer their medication at home or on the go. It empowers patients to take control of their own medication regimen. These aspects accelerate the segment growth.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to increasing prevalence of chronic diseases and rising healthcare expenditure. Countries like China, Japan, India, South Korea and Australia are major markets for healthcare products and devices due to their large and diverse population. The region has the presence of major key players such as Sanofi, Novo Nordisk and Sun Pharmaceutical Industries. Additionally, some governments in the Asia Pacific region have implemented policies and initiatives to promote the use of advanced medical devices, which has positively impacted the market for pen injectors.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, owing to the increasing prevalence of chronic diseases, the trend towards self-administration of drugs, and advancements in pen injector technology. Increasing incidence of diabetes and growing obese population is contributing toward market growth. The market is competitive with several key players such as Antares Pharma and Becton, Dickinson & Company. Further, technological advancements, the presence of a wide distribution network and increase in geriatric population, which require safer delivery devices, are other factors driving the North America market.

Key players in the market

Some of the key players profiled in the Pen Injectors Market include AstraZeneca, Becton, Dickinson and Company, Merck Group, Pfizer Inc., Eli Lilly and Company, Novartis AG, Sanofi, Novo Nordisk A/S, Biocon, Medtronic, Terumo Medical Corporation, Sun Pharmaceutical Industries Limited, GlaxoSmithKline PLC, Mylan N.V., Novo Nordisk, Owen Mumford Limited and Phillips-Medisize.

Key Developments:

In February 2023, Phillips-Medisize announced an addition to its portfolio of drug delivery devices, with its pen injector platform that is described as being more affordable to produce. The pen injector has been designed to match user expectation and experiences with disposable pen products, the company added.

In January 2023, Sun Pharmaceutical Industries Ltd launched its Phenobarbital sodium injection, SEZABY for treatment of neonatal seizures in the US. SEZABY is the first and only product approved by the US Food and Drug Administration (USFDA) for the treatment of neonatal seizures in term and preterm infants, Sun Pharma said in a regulatory filing.

In September 2022, Medtronic announced the European launch of its Smart MDI system, which combines personalized insulin dosing information from the InPen™ smart insulin pen with the power of predictive glucose alerts from the Guardian™ 4 smart continuous glucose monitoring (CGM) system.

Types Covered:
• Disposable
• Reusable

Dosages Covered:
• Fixed Dosage
• Variable Dosage
• Half-Unit Dosage
• Specialized Dosage
• Other Dosages

Therapies Covered:
• Diabetes
• Growth Hormone
• Osteoporosis
• Fertility
• Arthritis
• Cancer
• Multiple Sclerosis
• Autoimmune Diseases
• Anaphylaxis
• Cardiovascular Diseases
• Other Therapies

Distribution Channels Covered:
• Hospital Pharmacies
• Retail Pharmacies
• Online Stores
• Drug Stores

End Users Covered:
• Home-care Settings
• Hospital & Clinics

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements